What's Really Behind OpenAI's "Pause"
Спикеры
Ejaaz Ahamadeen
— Соведущий, подкаст Limitless (Bankless)
Josh Kale
— Соведущий, подкаст Limitless (Bankless)
Josh and Ejaaz cover OpenAI's pause on frontier reinforcement-learning training over misalignment concerns, AI cyber-threat scenarios, Moderna and Merck's Phase 3 melanoma mRNA vaccine breakthrough, Etched's $700 million raise, Unitree's overheated IPO, Stripe's acquisition of OpenRouter, and NVIDIA's $100 billion OpenAI data-center investment.
- OpenAI paused frontier RL training after the Hugging Face incident and internal misalignment concerns, with 20% of compute spent on monitoring.
- The hosts discuss escalating AI cyber risks, including malware, self-replicating prompts, and reasoning worms.
- Moderna and Merck reported positive Phase 3 melanoma results for a personalized mRNA cancer vaccine.
- Etched raised $700 million at a $21 billion valuation and shipped its first custom GPU rack to Jane Street.
- Unitree's IPO was heavily oversubscribed, but Ejaaz sees overhype because many humanoid sales are research-only.
- Stripe acquired OpenRouter for $7 billion on an AI token and inference infrastructure thesis.
- NVIDIA announced a $100 billion OpenAI data-center investment in Ohio, supporting NVIDIA revenue and AI power/optics infrastructure.
- Josh flagged capital formation as a possible next bottleneck for AI data center scaling.
Идеи
AI threats will drive cybersecurity demand.
AI models consistently beat human-written code and are especially strong in verifiable domains like cyber. The threat range includes AI-written malware, self-replicating prompts, and reasoning worms, so Josh expects a lot more cyber-related activity and demand ahead.
Personalized mRNA melanoma vaccine validates Moderna.
Moderna and Merck reported positive Phase 3 melanoma trial results for a personalized mRNA cancer vaccine. AI identified patient-specific tumor mutations to trigger an immune response, making cancer treatment personalized. Moderna stock surged roughly 250-300%, and approvals could come as soon as 2027.
Cheap sequencing plus AI accelerates biotech.
Biology is becoming an AI and software problem. Genome sequencing costs collapsed from billions of dollars and years of work to under $1,000 and hours, AI context windows can hold DNA sequences, and this enables hyper-specific personalized treatments. Josh sees biotech at a major inflection.
Unitree IPO looks overhyped and fragile.
Unitree's IPO was oversubscribed 5,500% and shares rose 542% on day one, but Ejaaz sees overhype because 40-60% of its humanoid robots have been sold only for research, not practical use. That makes recurring revenue questionable and the market dynamics look inflated with risk of a pullback.
NVIDIA locks in massive OpenAI infrastructure revenue.
NVIDIA is investing $100 billion in OpenAI's Ohio data center, which could scale to 8 gigawatts and generate an estimated $200-300 billion of revenue for NVIDIA from one customer alone. The contract also includes renewals for newer-generation GPUs, making NVIDIA a backstop for the AI buildout.
AI trade shifts to photonics/optics/power.
Ejaaz sees the next AI investment theme shifting to the photonics, optics, and power stack. NVIDIA is moving that way, having invested heavily in Lumentum and Coherent, and is now making a major play on power-side data center infrastructure.
Далее
This Bankless video, published August 21, 2026, features Josh Kale, Ejaaz Ahamadeen discussing CIBR, MRNA, XBI, 688836.SS, NVDA, LITE, COHR. 6 trade ideas extracted by AI with direction and confidence scoring.
Speakers: Josh Kale, Ejaaz Ahamadeen · Tickers: CIBR, MRNA, XBI, 688836.SS, NVDA, LITE, COHR